Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab rezetecan (SHR-A1811) in advanced HER2-positive rare solid tumors
ChiCTR2500112543Phase 2Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Nov 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab rezetecan in extramammary Paget disease (EMPD), transitional cell carcinoma (TCC), Not applicable (see rationale) and 4 more, sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Objective response rate (ORR). Planned start Nov 2025; status: not yet recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
extramammary Paget disease (EMPD)transitional cell carcinoma (TCC)Not applicable (see rationale)Bone and soft tissue sarcomacolorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2500112543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112543.